{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT06767800","nct_id":"NCT06767800","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct06767800. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"TQB2102 for Injection and bemarituzumab are administered intravenously every three weeks, while chemotherapy is given orally from Day 1 to Day 15, with each treatment cycle lasting 21 days.\n\nTQB2102 and bemosubicinumab for injection every three weeks and capecitabine Day1-Day15 administered orally in 21-day cycles","label":"TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy","type":"EXPERIMENTAL"},{"description":"TQB2102 for Injection and bemarituzumab are administered intravenously every three weeks, while chemotherapy is given orally from Day 1 to Day 15, with each treatment cycle lasting 21 days.","label":"TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy","type":"EXPERIMENTAL"},{"description":"TQB2102 for Injection and Penpulimab are administered intravenously every three weeks, while chemotherapy is given orally from Day 1 to Day 15, with each treatment cycle lasting 21 days.","label":"TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-09","type":"ESTIMATED"},"conditions":["Gastroesophageal Adenocarcinoma"],"enrollment":{"count":204,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"TQB2102 for injection (7.5 mg) +Benmelstobart+Chemotherapy","otherNames":[],"type":"DRUG"},{"name":"TQB2102 for injection (6 mg/7.5 mg) +Benmelstobart+Chemotherapy","otherNames":[],"type":"DRUG"},{"name":"TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy","otherNames":[],"type":"DRUG"}],"last_update":"2025-07-30","lead_sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","official_title":"Phase II Clinical Trial Evaluating the Efficacy and Safety of TQB2102 for Injection in Chemotherapy With Behmosubstituted Monoclonalb/Pembrolizumab ± Chemotherapy in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2026-09","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"Through study completion, an average of 1 year"}],"references":[],"start_date":{"date":"2024-11-21","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT06767800"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct06767800"}